HOWL
Werewolf Therapeutics, Inc.
$0.3820
-2.55%
$18.6M
No data for this timeframe.
Vol
Market Cap$18.6M
Cap SizeNano Cap
Inst. Holders5 funds
Inst. Value$1.8M
Inst. Activity2 buys / 3 sells
Insider Activity0B / 31S
Insider Net $-$1.4M
SEC Reports11
Recent Activity
Jun 8, 2026
Insider
EVNIN LUKE sold 60,547 shares
Director @ $0.4000 ($24.2K)
Jun 8, 2026
short_volume
Short Volume: HOWL — 59.2% short (0.3M / 0.5M)
Short: 296,905 | Exempt: 14,928 | TRF Vol: 501,352 | Short Ratio: 59.2% | Off-exchange volume (dark
Jun 5, 2026
Insider
EVNIN LUKE sold 24,946 shares
Director @ $0.4000 ($10.0K)
Jun 4, 2026
Insider
EVNIN LUKE sold 20,072 shares
Director @ $0.4400 ($8.8K)
May 28, 2026
SEC
A cluster of 8 Form 144 filings by MPM-affiliated entities (MPM Oncology Innovations Fund, MPM Asset Management, UBS Onc
144 — Impact 6/10
May 20, 2026
SEC
Director Luke Evnin and 10% owner RA Capital Management sold a combined $72K in HOWL stock over a 7-day window, represen
CLUSTER — Impact 4/10
May 18, 2026
SEC
Three MPM-affiliated funds (MPM BioVentures 2014, L.P., MPM BioVentures 2014 (B), L.P., and MPM Oncology Innovations Fun
144 — Impact 6/10
Inst.
BANK OF AMERICA CORP — TRIM
737,550 shares ($466.9K)
Price Targets
Historical data — last covering-analyst action Dec 2025. No current recommendation available.
$4.00 (Dec 2025)
Current $0.3745
Low $4.00
Median $4.00
High $4.00
1 analysts
$4.00
$4.00
Analyst Ratings
4Strong Buy
4Buy
2Hold
0Sell
0Strong Sell
Historical Analyst Actions
| Date | Firm | Action | Rating |
|---|---|---|---|
| Dec 19, 2025 | HC Wainwright & Co. | MAINTAIN | Buy → Buy |
Earnings Estimates
| Period | EPS Est. | Range | Growth | # |
|---|---|---|---|---|
| Current Q | $-0.28 ▲ +6.7% | $-0.28 — $-0.28 | 30% YoY | 1 |
| Next Q | $-0.22 ▲ +18.5% | $-0.22 — $-0.22 | 39% YoY | 1 |
| Current FY | $-0.89 ▲ +17.6% | $-0.89 — $-0.89 | 33% YoY | 1 |
| Next FY | $-0.99 ▲ +22.0% | $-0.99 — $-0.99 | -11% YoY | 1 |
Latest Reports
BEARISH
144
6/10
A cluster of 8 Form 144 filings by MPM-affiliated entities (MPM Oncology Innovations Fund, MPM Asset Management, UBS Onc
May 28, 2026
NEUTRAL
CLUSTER
4/10
Director Luke Evnin and 10% owner RA Capital Management sold a combined $72K in HOWL stock over a 7-day window, represen
May 20, 2026
Top Institutional Holders
| Fund | Value | Move |
|---|---|---|
| VANGUARD GROUP INC | $892.7K | — |
| BANK OF AMERICA CORP | $466.9K | TRIM |
| RENAISSANCE TECHNOLOGIES LLC | $429.4K | ADD |
| MORGAN STANLEY | $29.1K | DOUBLED |
| FMR LLC | $2.3K | TRIM |
Recent Insider Trades
| Date | Insider | Type | Value |
|---|---|---|---|
| Jun 8, 2026 | EVNIN LUKE | SELL | $24.2K |
| Jun 5, 2026 | EVNIN LUKE | SELL | $10.0K |
| Jun 4, 2026 | EVNIN LUKE | SELL | $8.8K |
| Jun 3, 2026 | EVNIN LUKE | SELL | $12.5K |
| Jun 2, 2026 | EVNIN LUKE | SELL | $13.3K |
5 institutional holders with $1.8M total value (2,872,996 shares) as of 2025-Q4. Top holders: VANGUARD, BANK, RENAISSANCE. Net selling activity: 3 institutions trimmed/exited vs 2 added.
Top Institutional Holders — 2025-Q4
| # | Fund | Shares | Value | % of Tracked | Last Move |
|---|---|---|---|---|---|
| 1 | VANGUARD GROUP INC | 1,408,047 | $892.7K | 49.0% | — |
| 2 | BANK OF AMERICA CORP /DE/ | 737,550 | $466.9K | 25.6% | TRIM -59.7% |
| 3 | RENAISSANCE TECHNOLOGIES LLC | 677,766 | $429.4K | 23.6% | ADD +48.6% |
| 4 | MORGAN STANLEY | 46,002 | $29.1K | 1.6% | DOUBLED +138.9% |
| 5 | FMR LLC | 3,631 | $2.3K | 0.1% | TRIM -67.8% |
Recent Position Changes
| Fund | Action | Prev Shares | Curr Shares | Change % | Value | Quarter |
|---|---|---|---|---|---|---|
| BANK OF AMERICA CORP /DE/ | TRIM | 1,830,292 | 737,550 | -59.7% | $466.9K | 2025-Q4 |
| RENAISSANCE TECHNOLOGIES LLC | ADD | 456,000 | 677,766 | +48.6% | $429.4K | 2025-Q4 |
| MORGAN STANLEY | DOUBLED | 19,252 | 46,002 | +138.9% | $29.1K | 2025-Q4 |
| FMR LLC | TRIM | 11,284 | 3,631 | -67.8% | $2.3K | 2025-Q4 |
| TWO SIGMA INVESTMENTS, LP | EXIT | 20,139 | 0 | -100.0% | $0.00 | 2025-Q4 |
| RENAISSANCE TECHNOLOGIES LLC | ADD | 316,300 | 456,000 | +44.2% | $898.3K | 2025-Q3 |
| TWO SIGMA INVESTMENTS, LP | TRIM | 45,422 | 20,139 | -55.7% | $39.7K | 2025-Q3 |
| MORGAN STANLEY | TRIM | 27,200 | 19,252 | -29.2% | $37.9K | 2025-Q3 |
| UBS Group AG | DOUBLED | 3,438 | 12,776 | +271.6% | $25.2K | 2025-Q3 |
| RENAISSANCE TECHNOLOGIES LLC | DOUBLED | 63,900 | 316,300 | +395.0% | $344.8K | 2025-Q2 |
| MORGAN STANLEY | TRIM | 107,827 | 27,200 | -74.8% | $29.6K | 2025-Q2 |
| FMR LLC | DOUBLED | 4,461 | 11,284 | +152.9% | $12.3K | 2025-Q2 |
| UBS Group AG | NEAR_EXIT | 17,688 | 3,438 | -80.6% | $3.7K | 2025-Q2 |
| WELLS FARGO & COMPANY/MN | NEAR_EXIT | 17,856 | 459 | -97.4% | $500.00 | 2025-Q2 |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | EXIT | 95,712 | 0 | -100.0% | $0.00 | 2025-Q2 |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | ADD | 71,860 | 95,712 | +33.2% | $93.1K | 2025-Q1 |
| TWO SIGMA INVESTMENTS, LP | TRIM | 93,440 | 58,132 | -37.8% | $56.5K | 2025-Q1 |
| UBS Group AG | TRIM | 30,493 | 17,688 | -42.0% | $17.2K | 2025-Q1 |
| FMR LLC | DOUBLED | 1,831 | 4,461 | +143.6% | $4.3K | 2025-Q1 |
| RENAISSANCE TECHNOLOGIES LLC | TRIM | 152,200 | 56,900 | -62.6% | $84.2K | 2024-Q4 |
| UBS Group AG | ADD | 15,479 | 30,493 | +97.0% | $45.1K | 2024-Q4 |
| WELLS FARGO & COMPANY/MN | ADD | 12,846 | 16,981 | +32.2% | $25.1K | 2024-Q4 |
| CITADEL ADVISORS LLC | ADD | 12,707 | 16,000 | +25.9% | $23.7K | 2024-Q4 |
| MORGAN STANLEY | DOUBLED | 49,012 | 119,040 | +142.9% | $252.4K | 2024-Q3 |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | NEW | — | 78,842 | — | $167.1K | 2024-Q3 |
2 unique insiders with 31 transactions. Net insider value: -$1.4M ($0.00 bought, $1.4M sold).
Insider Transactions
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Jun 8, 2026 | EVNIN LUKE | Director | SELL | 60,547 | $0.4000 | $24.2K |
| Jun 5, 2026 | EVNIN LUKE | Director | SELL | 24,946 | $0.4000 | $10.0K |
| Jun 4, 2026 | EVNIN LUKE | Director | SELL | 20,072 | $0.4400 | $8.8K |
| Jun 3, 2026 | EVNIN LUKE | Director | SELL | 29,749 | $0.4200 | $12.5K |
| Jun 2, 2026 | EVNIN LUKE | Director | SELL | 29,595 | $0.4500 | $13.3K |
| Jun 1, 2026 | EVNIN LUKE | Director | SELL | 80,459 | $0.4700 | $37.8K |
| May 29, 2026 | EVNIN LUKE | Director | SELL | 32,556 | $0.4500 | $14.7K |
| May 28, 2026 | EVNIN LUKE | Director | SELL | 27,698 | $0.4600 | $12.7K |
| May 27, 2026 | EVNIN LUKE | Director | SELL | 80,852 | $0.4800 | $38.8K |
| May 26, 2026 | EVNIN LUKE | Director | SELL | 67,950 | $0.4700 | $31.9K |
| May 22, 2026 | EVNIN LUKE | Director | SELL | 87,425 | $0.4500 | $39.3K |
| May 21, 2026 | EVNIN LUKE | Director | SELL | 36,387 | $0.4200 | $15.3K |
| May 20, 2026 | EVNIN LUKE | Director | SELL | 85,895 | $0.4300 | $36.9K |
| May 19, 2026 | EVNIN LUKE | Director | SELL | 62,970 | $0.4500 | $28.3K |
| May 18, 2026 | EVNIN LUKE | Director | SELL | 22,184 | $0.5000 | $11.1K |
| May 13, 2026 | EVNIN LUKE | Director | SELL | 44,679 | $0.5400 | $24.1K |
| May 12, 2026 | RA CAPITAL MANAGEMENT, L.P. | 10%+ Owner | SELL | 94,432 | $0.6400 | $60.4K |
| May 12, 2026 | EVNIN LUKE | Director | SELL | 67,885 | $0.6400 | $43.4K |
| May 11, 2026 | RA CAPITAL MANAGEMENT, L.P. | 10%+ Owner | SELL | 81,678 | $0.6700 | $54.7K |
| May 11, 2026 | EVNIN LUKE | Director | SELL | 33,948 | $0.6700 | $22.7K |
| May 8, 2026 | RA CAPITAL MANAGEMENT, L.P. | 10%+ Owner | SELL | 351,514 | $0.7100 | $249.6K |
| May 8, 2026 | EVNIN LUKE | Director | SELL | 305,741 | $0.7000 | $214.0K |
| May 7, 2026 | EVNIN LUKE | Director | SELL | 79,086 | $0.6300 | $49.8K |
| May 6, 2026 | EVNIN LUKE | Director | SELL | 14,635 | $0.6600 | $9.7K |
| May 5, 2026 | EVNIN LUKE | Director | SELL | 6,860 | $0.6900 | $4.7K |
| May 4, 2026 | EVNIN LUKE | Director | SELL | 47,963 | $0.7200 | $34.5K |
| May 1, 2026 | EVNIN LUKE | Director | SELL | 58,394 | $0.7300 | $42.6K |
| Apr 30, 2026 | EVNIN LUKE | Director | SELL | 168,262 | $0.7200 | $121.1K |
| Apr 29, 2026 | EVNIN LUKE | Director | SELL | 56,559 | $0.6900 | $39.0K |
| Apr 28, 2026 | EVNIN LUKE | Director | SELL | 95,412 | $0.7300 | $69.7K |
| Apr 27, 2026 | EVNIN LUKE | Director | SELL | 53,940 | $0.8500 | $45.8K |
11 SEC filing reports analyzed. Sentiment: 0 bullish, 6 bearish, 0 mixed, 5 neutral. Avg impact: 4.4/10.
BEARISH
144
6/10
A cluster of 8 Form 144 filings by MPM-affiliated entities (MPM Oncology Innovations Fund, MPM Asset
May 28, 2026
NEUTRAL
CLUSTER
4/10
Director Luke Evnin and 10% owner RA Capital Management sold a combined $72K in HOWL stock over a 7-
May 20, 2026
BEARISH
144
6/10
Three MPM-affiliated funds (MPM BioVentures 2014, L.P., MPM BioVentures 2014 (B), L.P., and MPM Onco
May 18, 2026
BEARISH
CLUSTER
6/10
Two insiders at Werewolf Therapeutics sold a total of $299K in open-market sales over a 7-day window
May 12, 2026
BEARISH
144
6/10
Two affiliated MPM entities (MPM Asset Management LLC and MPM Oncology Innovations Fund LP) filed Fo
May 11, 2026
NEUTRAL
144
2/10
MPM Asset Management Investors BV2014 LLC, a venture capital affiliate, filed a Form 144 indicating
May 1, 2026
NEUTRAL
144
4/10
Two major institutional holders—MPM BioVentures 2014 (B), L.P. and UBS Oncology Impact Fund L.P.—fil
May 1, 2026
BEARISH
144
5/10
Three affiliated MPM entities – MPM Asset Management LLC, MPM Oncology Innovations Fund LP, and MPM
May 1, 2026
NEUTRAL
144
2/10
MPM Asset Management LLC, a major shareholder of Werewolf Therapeutics, filed a Form 144 indicating
Apr 29, 2026
NEUTRAL
144
2/10
MPM Asset Management Investors BV2014 LLC, a venture capital fund, filed a Form 144 to sell 4,479 sh
Apr 29, 2026
BEARISH
144
5/10
Four MPM-affiliated funds filed Form 144 notices to sell an aggregate of 274,913 shares of Werewolf
Apr 27, 2026
No press releases analyzed yet. Press releases are collected from GlobeNewsWire and analyzed by the LLM pipeline.
Historical analyst distribution (last covering-analyst action Dec 2025): 80% buy across 10 analysts — 4 strong buy, 4 buy, 2 hold, 0 sell, 0 strong sell. No current recommendation available.
Analyst Price Targets
Historical data — last covering-analyst action Dec 2025. No current recommendation available.
$4.00 mean target (Dec 2025)
$4.00 Low
$4.00 High
| Metric | Value |
|---|---|
| Current Price | $0.3745 |
| Target Low | $4.00 |
| Target Mean | $4.00 |
| Target Median | $4.00 |
| Target High | $4.00 |
| # Analysts | 1 |
| Recommendation | — (no recent coverage) |
Earnings Estimates & Revisions
| Period | EPS Avg | EPS Low | EPS High | EPS Growth | 30d Rev. | Up/Down | Rev. Avg | Rev. Growth | Analysts |
|---|---|---|---|---|---|---|---|---|---|
| Current Q 2026-06-30 |
$-0.28 | $-0.28 | $-0.28 | 30.0% | +6.7% | 1↑ 0↓ | $0.0B | 0.0% | 1 |
| Next Q 2026-09-30 |
$-0.22 | $-0.22 | $-0.22 | 38.9% | +18.5% | 1↑ 0↓ | $0.0B | 0.0% | 1 |
| Current FY 2026-12-31 |
$-0.89 | $-0.89 | $-0.89 | 32.6% | +17.6% | 0↑ 1↓ | $0.0B | 0.0% | 1 |
| Next FY 2027-12-31 |
$-0.99 | $-0.99 | $-0.99 | -11.2% | +22.0% | 1↑ 0↓ | $0.0B | 0.0% | 1 |
Current Quarter EPS Revision History
| Timepoint | EPS Estimate | Change |
|---|---|---|
| Current | $-0.280 | |
| 7d ago | $-0.300 | +0.020 |
| 30d ago | $-0.300 | +0.020 |
| 60d ago | $-0.333 | +0.053 |
| 90d ago | $-0.333 | +0.053 |
1 analyst firms have rated this stock: 0 upgrades, 0 downgrades, 0 initiations.
Historical Analyst Actions
| Date | Analyst Firm | Action | Previous Rating | New Rating |
|---|---|---|---|---|
| Dec 19, 2025 | HC Wainwright & Co. | MAINTAIN | Buy | Buy |
Monthly Consensus History
| Period | Strong Buy | Buy | Hold | Sell | Strong Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Jun 1, 2026 | 4 | 4 | 2 | 0 | 0 | 80% | |
| May 1, 2026 | 4 | 4 | 2 | 0 | 0 | 80% | |
| Apr 1, 2026 | 5 | 4 | 2 | 0 | 0 | 82% | |
| Mar 1, 2026 | 5 | 4 | 3 | 0 | 0 | 75% | |
| Feb 1, 2026 | 5 | 4 | 3 | 0 | 0 | 75% | |
| Jan 1, 2026 | 5 | 4 | 3 | 0 | 0 | 75% |
Strong BuyBuyHoldSellStrong Sell
No congressional trading data available for this ticker. Data is sourced from Senate and House financial disclosure filings.
No Reddit sentiment data available yet. Sentiment is analyzed from Reddit investment communities on a rolling basis.
Jun 8, 2026
short_volume
Short Volume: HOWL — 59.2% short (0.3M / 0.5M)
Short: 296,905 | Exempt: 14,928 | TRF Vol: 501,352 | Short Ratio: 59.2% | Off-exchange volume (dark pool + OTC)
May 7, 2026
earnings_calendar
HOWL Q1 2026 Earnings Scheduled — 2026-05-07
May 1, 2026
earnings_calendar
HOWL Q1 2026 Earnings Scheduled — 2026-05-01
Mar 27, 2026
earnings
Werewolf Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Corporate Updates
Company continues to evaluate strategic options to maximize shareholder value <pre>Company continues to evaluate strategic options to maximize shareho
Mar 19, 2026
earnings_calendar
HOWL Q4 2025 Earnings After Market Close — 2026-03-19
Mar 2, 2026
earnings_calendar
HOWL Q4 2025 Earnings After Market Close — 2026-03-02